Döhr O[au] - Search Results

Year	Number of Results
1982	1
1983	1
1985	1
1994	3
1995	1
1996	2
1997	3
1998	1
2000	1
2001	1
2007	1
2013	1
2014	1
2020	1
2022	0

1

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.

Schulze VK, Klar U, Kosemund D, Wengner AM, Siemeister G, Stöckigt D, Neuhaus R, Lienau P, Bader B, Prechtl S, Holton SJ, Briem H, Marquardt T, Schirok H, Jautelat R, Bohlmann R, Nguyen D, Fernández-Montalván AE, Bömer U, Eberspaecher U, Brüning M, Döhr O, Raschke M, Kreft B, Mumberg D, Ziegelbauer K, Brands M, von Nussbaum F, Koppitz M. Schulze VK, et al. Among authors: dohr o. J Med Chem. 2020 Aug 13;63(15):8025-8042. doi: 10.1021/acs.jmedchem.9b02035. Epub 2020 Apr 27. J Med Chem. 2020. PMID: 32338514

2

Preclinical safety evaluation of Gd-EOB-DTPA (Primovist).

Döhr O, Hofmeister R, Treher M, Schweinfurth H. Döhr O, et al. Invest Radiol. 2007 Dec;42(12):830-41. doi: 10.1097/RLI.0b013e318137a471. Invest Radiol. 2007. PMID: 18007155

3

[Delirium tremens].

Døhr O. Døhr O. Ugeskr Laeger. 1982 Jun 21;144(25):1831-3. Ugeskr Laeger. 1982. PMID: 7135602 Danish. No abstract available.

4

Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer.

Lesche R, Kettschau G, Gromov AV, Böhnke N, Borkowski S, Mönning U, Hegele-Hartung C, Döhr O, Dinkelborg LM, Graham K. Lesche R, et al. Among authors: dohr o. Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):89-101. doi: 10.1007/s00259-013-2527-3. Epub 2013 Aug 17. Eur J Nucl Med Mol Imaging. 2014. PMID: 23955632

5

Engineering of a functional human NADH-dependent cytochrome P450 system.

Döhr O, Paine MJ, Friedberg T, Roberts GC, Wolf CR. Döhr O, et al. Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):81-6. doi: 10.1073/pnas.98.1.81. Proc Natl Acad Sci U S A. 2001. PMID: 11136248 Free PMC article.

6

Increased frequencies of cytochrome P4501A1 polymorphisms in infertile men.

Fritsche E, Schuppe HC, Döhr O, Ruzicka T, Gleichmann E, Abel J. Fritsche E, et al. Among authors: dohr o. Andrologia. 1998 May-Jun;30(3):125-8. doi: 10.1111/j.1439-0272.1998.tb01387.x. Andrologia. 1998. PMID: 9635090

7

Modulation of growth factor expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin.

Döhr O, Vogel C, Abel J. Döhr O, et al. Exp Clin Immunogenet. 1994;11(2-3):142-8. doi: 10.1159/000424205. Exp Clin Immunogenet. 1994. PMID: 7826663 Review.

8

Transforming growth factor-beta 1 inhibits TCDD-induced cytochrome P450IA1 expression in human lung cancer A549 cells.

Vogel C, Döhr O, Abel J. Vogel C, et al. Among authors: dohr o. Arch Toxicol. 1994;68(5):303-7. doi: 10.1007/s002040050073. Arch Toxicol. 1994. PMID: 8085941

9

Different response of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-sensitive genes in human breast cancer MCF-7 and MDA-MB 231 cells.

Döhr O, Vogel C, Abel J. Döhr O, et al. Arch Biochem Biophys. 1995 Aug 20;321(2):405-12. doi: 10.1006/abbi.1995.1411. Arch Biochem Biophys. 1995. PMID: 7646066

10

Dose-response relationship of cytochrome P4501b1 mRNA induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin in livers of C57BL/6J and DBA/2J mice.

Abel J, Li W, Döhr O, Vogel C, Donat S. Abel J, et al. Among authors: dohr o. Arch Toxicol. 1996;70(8):510-3. doi: 10.1007/s002040050307. Arch Toxicol. 1996. PMID: 8783816

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results